
Anti-Inflammatory Drugs Market - Global Outlook & Forecast 2022-2027
Description
Anti-Inflammatory Drugs Market - Global Outlook & Forecast 2022-2027
The study considers a detailed scenario of the present global anti-inflammatory drugs market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.
The global anti-inflammatory drugs market is expected to grow at a CAGR of 6.78% during 2022-2027
MARKET GROWTH AND OPPORTUNITIES
In 2021, North America was the major revenue contributor and accounted for 41.38% in the global anti-inflammatory drugs market in 2021 and witness the highest incremental growth of $20.88 billion during the forecast period.
Increasing population, the emergence of autoimmune diseases, expansion of demand, increase in pharma and biopharma facilities, and the advent of COVID-19 are major factors to boost the demand for anti-inflammatory drugs in Europe.
Segmentation by Geography
Canada
France
UK
Italy
Spain
India
Japan
Australia
South Korea
Mexico
Argentina
Saudi Arabia
Turkey
VENDOR ANALYSIS
Key Vendors
The study considers a detailed scenario of the present global anti-inflammatory drugs market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.
The global anti-inflammatory drugs market is expected to grow at a CAGR of 6.78% during 2022-2027
MARKET GROWTH AND OPPORTUNITIES
- Rising OTC Buying behavior of Anti-inflammatory drugs Among Larger Patient Groups
- Rising Prevalence of a Broad Range of Inflammatory Diseases
- Increasing Use of Biologics for Treating Inflammatory Diseases
- Based on drug class, biologics and biosimilars is the major contributor in the global anti-inflammatory drugs market, and it is likely to witness high incremental growth of $33.64 billion during the forecast period.
- The global anti-inflammatory drugs market is highly competitive and fragmented even though the leading companies are constantly consolidating their market position through strategic and high-profile mergers and acquisitions.
- Biologics & Biosimilars
- NSAIDs
- Steroids
- Others
- Autoimmune Diseases
- Respiratory Diseases
- Others
- Parenteral
- Oral
- Topical
- Inhalation
In 2021, North America was the major revenue contributor and accounted for 41.38% in the global anti-inflammatory drugs market in 2021 and witness the highest incremental growth of $20.88 billion during the forecast period.
Increasing population, the emergence of autoimmune diseases, expansion of demand, increase in pharma and biopharma facilities, and the advent of COVID-19 are major factors to boost the demand for anti-inflammatory drugs in Europe.
Segmentation by Geography
- North America
Canada
- Europe
France
UK
Italy
Spain
- APAC
India
Japan
Australia
South Korea
- Latin America
Mexico
Argentina
- Middle East & Africa
Saudi Arabia
Turkey
VENDOR ANALYSIS
Key Vendors
- AbbVie
- Amgen
- Biogen
- Bristol Myers Squibb
- Eli Lilly & Company
- F. Hoffmann-La Roche
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co
- Novartis
- Pfizer
- Actiza Pharmaceutical
- Allergan
- Antibe Therapeutics
- Aurinia Pharmaceuticals
- AstraZeneca
- Aurobindo Pharma
- Bayer
- Bio-Thera Solutions
- Cadila Pharmaceuticals
- Cipla
- Celltrion
- CENTURION REMEDIES
- Dr. Reddy's Laboratories
- Eisai
- Gilead Sciences
- Glenmark Pharmaceuticals
- Lupin
- Medico Remedies
- Regeneron Pharmaceuticals
- Samsung Bioepis
- Sanofi
- Sun Pharmaceutical Industries
- Swedish Orphan Biovitrum
- UCB
- FUJIFILM KYOWA KIRIN BIOLOGICS
- Teva pharmaceuticals
Table of Contents
326 Pages
- 1 RESEARCH METHODOLOGY
- 2 RESEARCH OBJECTIVES
- 3 RESEARCH PROCESS
- 4 SCOPE & COVERAGE
- 4.1 MARKET DEFINITION
- 4.1.1 INCLUSIONS
- 4.1.2 EXCLUSIONS
- 4.1.3 MARKET ESTIMATION CAVEATS
- 4.2 BASE YEAR
- 4.3 SCOPE OF THE STUDY
- 4.4 MARKET SEGMENTATION
- 4.4.1 MARKET SEGMENTATION BY DRUG CLASS
- 4.4.2 MARKET SEGMENTATION BY APPLICATION
- 4.4.3 MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION
- 4.4.4 MARKET SEGMENTATION BY GEOGRAPHY
- 5 REPORT ASSUMPTIONS & CAVEATS
- 5.1 KEY CAVEATS
- 5.2 CURRENCY CONVERSION
- 5.3 MARKET DERIVATION
- 6 MARKET AT A GLANCE
- 7 INTRODUCTION
- 7.1 OVERVIEW
- 7.1.1 EPIDEMIOLOGY OF INFLAMMATORY DISEASES
- 7.1.2 TREATMENT OF INFLAMMATORY DISEASES
- 8 MARKET OPPORTUNITIES & TRENDS
- 8.1 PROMISING INVESTIGATIONAL DRUGS IN CLINICAL TRIAL PIPELINES
- 8.2 SURGE IN AVAILABILITY OF APPROVED BIOSIMILARS TO TREAT INFLAMMATORY DISEASES
- 8.3 RISE IN COMMERCIALIZATION OF ANTI-INFLAMMATORY DRUGS
- 9 MARKET GROWTH ENABLERS
- 9.1 PREFERENCE FOR ANTI-INFLAMMATORY DRUGS AMONG PATIENT GROUPS
- 9.2 RISING PREVALENCE OF INFLAMMATORY DISEASES
- 9.3 GROWING USE OF BIOLOGICS TO TREAT INFLAMMATORY DISEASES
- 10 MARKET RESTRAINTS
- 10.1 PATENT EXPIRATION OF ANTI-INFLAMMATORY DRUGS
- 10.2 SIDE-EFFECTS OF ANTI-INFLAMMATORY DRUGS
- 10.3 PRODUCT RECALLS DUE TO STRINGENT REGULATORY GUIDELINES
- 11 MARKET LANDSCAPE
- 11.1 MARKET OVERVIEW
- 11.1.1 MARKET SIZE & FORECAST
- 11.1.2 INSIGHTS BY GEOGRAPHY
- 11.1.3 INSIGHTS BY DRUG CLASS
- 11.1.4 INSIGHTS BY APPLICATION
- 11.1.5 INSIGHTS BY ROUTE OF ADMINISTRATION
- 11.2 FIVE FORCES ANALYSIS
- 11.2.1 THREAT OF NEW ENTRANTS
- 11.2.2 BARGAINING POWER OF SUPPLIERS
- 11.2.3 BARGAINING POWER OF BUYERS
- 11.2.4 THREAT OF SUBSTITUTES
- 11.2.5 COMPETITIVE RIVALRY
- 12 DRUG CLASS
- 12.1 MARKET SNAPSHOT & GROWTH ENGINE
- 12.2 MARKET OVERVIEW
- 12.3 BIOLOGICS & BIOSIMILARS
- 12.3.1 MARKET OVERVIEW
- 12.3.2 MARKET SIZE & FORECAST
- 12.4 NSAIDS
- 12.4.1 MARKET OVERVIEW
- 12.4.2 MARKET SIZE & FORECAST
- 12.5 STEROIDS
- 12.5.1 MARKET OVERVIEW
- 12.5.2 MARKET SIZE & FORECAST
- 12.1 OTHERS
- 12.1.1 MARKET OVERVIEW
- 12.1.2 MARKET SIZE & FORECAST
- 13 APPLICATION
- 13.1 MARKET SNAPSHOT & GROWTH ENGINE
- 13.2 MARKET OVERVIEW
- 13.3 AUTOIMMUNE DISEASES
- 13.3.1 MARKET OVERVIEW
- 13.3.2 MARKET SIZE & FORECAST
- 13.4 RESPIRATORY DISEASES
- 13.4.1 MARKET OVERVIEW
- 13.4.2 MARKET SIZE & FORECAST
- 13.5 OTHERS
- 13.5.1 MARKET OVERVIEW
- 13.5.2 MARKET SIZE & FORECAST
- 14 ROUTE OF ADMINISTRATION
- 14.1 MARKET SNAPSHOT & GROWTH ENGINE
- 14.2 MARKET OVERVIEW
- 14.3 PARENTERAL
- 14.3.1 MARKET OVERVIEW
- 14.3.2 MARKET SIZE & FORECAST
- 14.4 ORAL
- 14.4.1 MARKET OVERVIEW
- 14.4.2 MARKET SIZE & FORECAST
- 14.5 TOPICAL
- 14.5.1 MARKET OVERVIEW
- 14.5.2 MARKET SIZE & FORECAST
- 14.6 INHALATION
- 14.6.1 MARKET OVERVIEW
- 14.6.2 MARKET SIZE & FORECAST
- 15 GEOGRAPHY
- 15.1 MARKET SNAPSHOT & GROWTH ENGINE
- 15.2 GEOGRAPHIC OVERVIEW
- 16 NORTH AMERICA
- 16.1 MARKET OVERVIEW
- 16.2 MARKET SIZE & FORECAST
- 16.2.1 NORTH AMERICA: DRUG CLASS SEGMENTATION
- 16.2.2 NORTH AMERICA: INDICATION SEGMENTATION
- 16.2.3 NORTH AMERICA: ROUTE OF ADMINISTERATION SEGMENTATION
- 16.3 KEY COUNTRIES
- 16.3.1 US: MARKET SIZE & FORECAST
- 16.3.2 CANADA: MARKET SIZE & FORECAST
- 17 EUROPE
- 17.1 MARKET OVERVIEW
- 17.2 MARKET SIZE & FORECAST
- 17.2.1 EUROPE: DRUG CLASS SEGMENTATION
- 17.2.2 EUROPE: APPLICATION SEGMENTATION
- 17.2.3 EUROPE: ROUTE OF ADMINISTRATION SEGMENTATION
- 17.3 KEY COUNTRIES
- 17.3.1 GERMANY: MARKET SIZE & FORECAST
- 17.3.2 THE UK: MARKET SIZE & FORECAST
- 17.3.3 FRANCE: MARKET SIZE & FORECAST
- 17.3.4 ITALY: MARKET SIZE & FORECAST
- 17.3.5 SPAIN: MARKET SIZE & FORECAST
- 18 APAC
- 18.1 MARKET OVERVIEW
- 18.2 MARKET SIZE & FORECAST
- 18.2.1 APAC: DRUG CLASS SEGMENTATION
- 18.2.2 APAC: APPLICATION SEGMENTATION
- 18.2.3 APAC: ROUTE OF ADMINISTERATION SEGMENTATION
- 18.3 KEY COUNTRIES
- 18.3.1 CHINA: MARKET SIZE & FORECAST
- 18.3.2 JAPAN: MARKET SIZE & FORECAST
- 18.3.3 INDIA: MARKET SIZE & FORECAST
- 18.3.4 AUSTRALIA: MARKET SIZE & FORECAST
- 18.3.5 SOUTH KOREA: MARKET SIZE & FORECAST
- 19 LATIN AMERICA
- 19.1 MARKET OVERVIEW
- 19.2 MARKET SIZE & FORECAST
- 19.2.1 LATIN AMERICA: DRUG CLASS SEGMENTATION
- 19.2.2 LATIN AMERICA: APPLICATION SEGMENTATION
- 19.2.3 LATIN AMERICA: ROUTE OF ADMINISTRATION SEGMENTATION
- 19.3 KEY COUNTRIES
- 19.3.1 BRAZIL: MARKET SIZE & FORECAST
- 19.3.2 MEXICO: MARKET SIZE & FORECAST
- 19.3.3 ARGENTINA : MARKET SIZE & FORECAST
- 20 MIDDLE EAST AND AFRICA
- 20.1 MARKET OVERVIEW
- 20.2 MARKET SIZE & FORECAST
- 20.2.1 MIDDLE EAST & AFRICA: DRUG CLASS SEGMENTATION
- 20.2.2 MIDDLE EAST & AFRICA: APPLICATION SEGMENTATION
- 20.2.3 MIDDLE EAST & AFRICA: ROUTE OF ADMINISTERATION SEGMENTATION
- 20.3 KEY COUNTRIES
- 20.3.1 TURKEY: MARKET SIZE & FORECAST
- 20.3.2 SOUTH AFRICA: MARKET SIZE & FORECAST
- 20.3.3 SAUDI ARABIA: MARKET SIZE & FORECAST
- 21 COMPETITIVE LANDSCAPE
- 21.1 COMPETITION OVERVIEW
- 21.2 MARKET SHARE ANALYSIS
- 22 KEY COMPANIES PROFILES
- 22.1 ABBVIE
- 22.1.1 BUSINESS OVERVIEW
- 22.1.2 PRODUCT OFFERINGS
- 22.1.3 KEY STRATEGIES
- 22.1.4 KEY STRENGTHS
- 22.1.5 KEY OPPORTUNITIES
- 22.2 AMGEN
- 22.2.1 BUSINESS OVERVIEW
- 22.2.2 PRODUCT OFFERINGS
- 22.2.3 KEY STRATEGIES
- 22.2.4 KEY STRENGTHS
- 22.2.5 KEY OPPORTUNITIES
- 22.3 BIOGEN
- 22.3.1 BUSINESS OVERVIEW
- 22.3.2 PRODUCT OFFERINGS
- 22.3.3 KEY STRATEGIES
- 22.3.4 KEY STRENGTHS
- 22.3.5 KEY OPPORTUNITIES
- 22.4 BRISTOL MYERS SQUIBB
- 22.4.1 BUSINESS OVERVIEW
- 22.4.2 PRODUCT OFFERINGS
- 22.4.3 KEY STRATEGIES
- 22.4.4 KEY STRENGTHS
- 22.4.5 KEY OPPORTUNITIES
- 22.5 ELI LILLY & COMPANY
- 22.5.1 BUSINESS OVERVIEW
- 22.5.2 PRODUCT OFFERINGS
- 22.5.3 KEY STRATEGIES
- 22.5.4 KEY STRENGTHS
- 22.5.5 KEY OPPORTUNITIES
- 22.6 F. HOFFMANN-LA ROCHE
- 22.6.1 BUSINESS OVERVIEW
- 22.6.2 PRODUCT OFFERINGS
- 22.6.3 KEY STRATEGIES
- 22.6.4 KEY STRENGTHS
- 22.6.5 KEY OPPORTUNITIES
- 22.7 GLAXOSMITHKLINE
- 22.7.1 BUSINESS OVERVIEW
- 22.7.2 PRODUCT OFFERINGS
- 22.7.3 KEY STRATEGIES
- 22.7.4 KEY STRENGTHS
- 22.7.5 KEY OPPORTUNITIES
- 22.8 JOHNSON & JOHNSON
- 22.8.1 BUSINESS OVERVIEW
- 22.8.2 PRODUCT OFFERINGS
- 22.8.3 KEY STRATEGIES
- 22.8.4 KEY STRENGTHS
- 22.8.5 KEY OPPORTUNITIES
- 22.9 MERCK & CO
- 22.9.1 BUSINESS OVERVIEW
- 22.9.2 PRODUCT OFFERINGS
- 22.9.3 KEY STRATEGIES
- 22.9.4 KEY STRENGTHS
- 22.9.5 KEY OPPORTUNITIES
- 22.10 NOVARTIS
- 22.10.1 BUSINESS OVERVIEW
- 22.10.2 PRODUCT OFFERINGS
- 22.10.3 KEY STRATEGIES
- 22.10.4 KEY STRENGTHS
- 22.10.5 KEY OPPORTUNITIES
- 22.11 PFIZER
- 22.11.1 BUSINESS OVERVIEW
- 22.11.2 PRODUCT OFFERINGS
- 22.11.3 KEY STRATEGIES
- 22.11.4 KEY STRENGTHS
- 22.11.5 KEY OPPORTUNITIES
- 23 OTHER PROMINENT VENDORS
- 23.1 ACTIZA PHARMACEUTICAL
- 23.1.1 BUSINESS OVERVIEW
- 23.1.2 PRODUCT OFFERINGS
- 23.2 ALLERGAN
- 23.2.1 BUSINESS OVERVIEW
- 23.2.2 PRODUCT OFFERINGS
- 23.3 ANTIBE THERAPEUTICS
- 23.3.1 BUSINESS OVERVIEW
- 23.3.2 PRODUCT OFFERINGS
- 23.4 AURINIA PHARMACEUTICALS
- 23.4.1 BUSINESS OVERVIEW
- 23.4.2 PRODUCT OFFERINGS
- 23.5 ASTRAZENECA
- 23.5.1 BUSINESS OVERVIEW
- 23.5.2 PRODUCT OFFERINGS
- 23.6 AUROBINDO PHARMA
- 23.6.1 BUSINESS OVERVIEW
- 23.6.2 PRODUCT OFFERINGS
- 23.7 BAYER
- 23.7.1 BUSINESS OVERVIEW
- 23.7.2 PRODUCT OFFERINGS
- 23.8 BIO-THERASOLUTIONS
- 23.8.1 BUSINESS OVERVIEW
- 23.8.2 PRODUCT OFFERINGS
- 23.9 CADILA PHARMACEUTICALS
- 23.9.1 BUSINESS OVERVIEW
- 23.9.2 PRODUCT OFFERINGS
- 23.10 CIPLA
- 23.10.1 BUSINESS OVERVIEW
- 23.10.2 PRODUCT OFFERINGS
- 23.11 CELLTRION
- 23.11.1 BUSINESS OVERVIEW
- 23.11.2 PRODUCT OFFERINGS
- 23.12 CENTURION REMEDIES
- 23.12.1 BUSINESS OVERVIEW
- 23.12.2 PRODUCT OFFERINGS
- 23.13 DR. REDDY’S LABORATORIES
- 23.13.1 BUSINESS OVERVIEW
- 23.13.2 PRODUCT OFFERINGS
- 23.14 EISAI
- 23.14.1 BUSINESS OVERVIEW
- 23.15 GILEAD SCIENCES
- 23.15.1 BUSINESS OVERVIEW
- 23.16 GLENMARK PHARMACEUTICALS
- 23.16.1 BUSINESS OVERVIEW
- 23.16.2 PRODUCT OFFERINGS
- 23.17 LUPIN
- 23.17.1 BUSINESS OVERVIEW
- 23.17.2 PRODUCT OFFERINGS
- 23.18 MEDICO REMEDIES
- 23.18.1 BUSINESS OVERVIEW
- 23.18.2 PRODUCT OFFERINGS
- 23.19 REGENERON PHARMACEUTICALS
- 23.19.1 BUSINESS OVERVIEW
- 23.19.2 PRODUCT OFFERINGS
- 23.20 SAMSUNG BIOEPIS
- 23.20.1 BUSINESS OVERVIEW
- 23.20.2 PRODUCT OFFERINGS
- 23.21 SANOFI
- 23.21.1 BUSINESS OVERVIEW
- 23.21.2 PRODUCT OFFERINGS
- 23.22 SUN PHARMACEUTICAL INDUSTRIES
- 23.22.1 BUSINESS OVERVIEW
- 23.22.2 PRODUCT OFFERINGS
- 23.23 SWEDISH ORPHAN BIOVITRUM
- 23.23.1 BUSINESS OVERVIEW
- 23.23.2 PRODUCT OFFERINGS
- 23.24 UCB
- 23.24.1 BUSINESS OVERVIEW
- 23.24.2 PRODUCT OFFERINGS
- 23.25 FUJIFILM KYOWA KIRIN BIOLOGICS
- 23.25.1 BUSINESS OVERVIEW
- 23.25.2 PRODUCT OFFERINGS
- 24 REPORT SUMMARY
- 24.1 KEY TAKEAWAYS
- 24.2 STRATEGIC RECOMMENDATIONS
- 25 QUANTITATIVE SUMMARY
- 25.1 MARKET BY DRUG CLASS
- 25.1.1 NORTH AMERICA: DRUG CLASS SEGMENTATION
- 25.1.3 EUROPE: DRUG CLASS SEGMENTATION
- 25.1.4 APAC: DRUG CLASS SEGMENTATION
- 25.1.5 LATIN AMERICA: DRUG CLASS SEGMENTATION
- 25.1.6 MIDDLE EAST & AFRICA: DRUG CLASS SEGMENTATION
- 25.2 MARKET BY APPLICATION
- 25.2.1 NORTH AMERICA: APPLICATION SEGMENTATION
- 25.2.2 EUROPE: APPLICATION SEGMENTATION
- 25.2.3 APAC: APPLICATION SEGMENTATION
- 25.2.4 LATIN AMERICA: APPLICATION SEGMENTATION
- 25.2.5 MIDDLE EAST & AFRICA: APPLICATION SEGMENTATION
- 25.3 MARKET BY ROUTE OF ADMINISTRATION
- 25.3.1 NORTH AMERICA: ROUTE OF ADMINISTRATION
- 25.3.2 EUROPE: ROUTE OF ADMINISTRATION
- 25.3.3 APAC: ROUTE OF ADMINISTRATION
- 25.3.4 LATIN AMERICA: ROUTE OF ADMINISTRATION
- 25.3.5 MIDDLE EAST & AFRICA: ROUTE OF ADMINISTRATION
- 25.4 MARKET BY GEOGRAPHY
- 25.5.1 BIOLOGICS & BIOSIMILARS: GEOGRAPHY SEGMENTATION
- 25.5.2 NSAIDS: GEOGRAPHY SEGMENTATION
- 25.5.3 STEROIDS: GEOGRAPHY SEGMENTATION
- 25.5.4 OTHERS: GEOGRAPHY SEGMENTATION
- 25.5.5 AUTOIMMUNE DISEASES: GEOGRAPHY SEGMENTATION
- 25.5.6 RESPIRATORY DISEASES: GEOGRAPHY SEGMENTATION
- 25.5.7 OTHER DISEASES: GEOGRAPHY SEGMENTATION
- 25.5.8 PARENTERAL: GEOGRAPHY SEGMENTATION
- 25.5.9 ORAL: GEOGRAPHY SEGMENTATION
- 25.5.10 TOPICAL: GEOGRAPHY SEGMENTATION
- 25.5.11 INHALATIONAL: GEOGRAPHY SEGMENTATION
- 26 APPENDIX
- 26.1 ABBREVIATIONS
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.